Levomilnacipran

Levomilnacipran ((1S,2R) -Milnacipran) is the enantiomer of Milnacipran (HY-B0168) and a strong substrate of P-gp that can cross the blood-brain barrier. Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor, with IC50 values of 10.5 nM and 19.0 nM, and Ki values of 92.2 nM and 1.2 nM for human norepinephrine transporter (NET) and serotonin transporter (SERT), respectively. Levomilnacipran has antidepressant and anxiolytic activities. Levomilnacipran hydrochloride can be used for the research of depression[1][2][3][4].

Product Specifications

CAS Number

[96847-54-0]

Product Name Alternative

(1S,2R) -Milnacipran; F2695

UNSPSC

12352005

Hazard Statement

H315-H319-H320

Target

Akt; mTOR; P-glycoprotein; PI3K; Serotonin Transporter; Trk Receptor

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/levomilnacipran.html

Solubility

10 mM in DMSO

Smiles

O=C(N(CC)CC)[C@@]1([C@@H](C1)CN)C2=CC=CC=C2

Molecular Formula

C15H22N2O

Molecular Weight

246.35

Precautions

P264-P280-P302+P352-P305+P351+P338-P362

References & Citations

[1]Asnis GM, et al. Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr Dis Treat. 2015 Jan 9;11:125-35.|[2]Bundgaard C, et al. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo. Neuropharmacology. 2016 Apr;103:104-11.|[3]Wu Y, et al. Levomilnacipran Improves Lipopolysaccharide-Induced Dysregulation of Synaptic Plasticity and Depression-Like Behaviors via Activating BDNF/TrkB Mediated PI3K/Akt/mTOR Signaling Pathway. Mol Neurobiol. 2024 Jul;61 (7) :4102-4115.|[4]Auclair AL, et al. Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology. 2013 Jul;70:338-47.